Silence Therapeutics Files 2024 10-K
Ticker: SLNCF · Form: 10-K · Filed: Feb 27, 2025 · CIK: 1479615
| Field | Detail |
|---|---|
| Company | Silence Therapeutics PLC (SLNCF) |
| Form Type | 10-K |
| Filed Date | Feb 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, pharmaceutical, annual-report
TL;DR
Silence Therapeutics filed its 2024 10-K, detailing financials and operations for the year ending Dec 31, 2024.
AI Summary
Silence Therapeutics plc filed its 2024 10-K on February 27, 2025, reporting on its operations for the fiscal year ending December 31, 2024. The company, incorporated in X0 and headquartered in London, operates in the pharmaceutical preparations sector. Key financial data and operational details for the period are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with a comprehensive overview of Silence Therapeutics' financial health, strategic initiatives, and risk factors for the fiscal year 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Silence Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (The period covered by the 10-K filing.)
- 2025-02-27 — Filing Date (The date Silence Therapeutics submitted its 10-K to the SEC.)
Key Players & Entities
- Silence Therapeutics plc (company) — Filer of the 10-K
- 2024-12-31 (date) — End of the reporting period
- 2025-02-27 (date) — Filing date of the 10-K
- London (location) — Company headquarters
- AstraZeneca (company) — Mentioned in relation to a collaboration agreement
- Hansoh (company) — Mentioned in relation to a research collaboration
FAQ
What was the primary business of Silence Therapeutics plc during the fiscal year 2024?
Silence Therapeutics plc operates in the Pharmaceutical Preparations sector, as indicated by its SIC code [2834].
When did Silence Therapeutics plc file its 10-K report for the fiscal year ending December 31, 2024?
The 10-K report was filed on February 27, 2025.
Where is Silence Therapeutics plc headquartered?
The company's business address is listed as 72 Hammersmith Road, London, W14 8TH.
Are there any significant past collaborations mentioned in the filing data?
Yes, the filing data references a 'Collaboration Agreement With AstraZeneca' dated May 31, 2021, and a 'Research Collaboration Hansoh' starting January 1, 2024.
What is the SEC file number for Silence Therapeutics plc?
The SEC file number for Silence Therapeutics plc is 001-39487.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on February 27, 2025 regarding Silence Therapeutics plc (SLNCF).